ABSTRACT
Thus, second-and third-generation devices were developed using continuous-flow pumps. These devices were smaller, allowing implantation in a broader population including women and children. The improved technology allowed for lengthened battery life, longer support times, and overall better quality of life for patients with advanced heart failure.3 Continuous-flow devices have continued to dominate the market since their introduction and are implanted in more than 90% of patients with heart failure.4
